USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Dec. 20, 2024 /PRNewswire/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights , underscoring major strides in cancer research and ongoing innovation. However, the optimism is tempered by a troubling finding: a significant global rise in early-onset colorectal cancer cases . This unsettling trend comes as the medical community grapples with the lingering effects of the COVID-19 pandemic. A recent Nature article revealed how disruptions in cancer care—particularly delays in screenings, diagnoses, and treatments—have likely exacerbated the progression of advanced disease, diminished survival rates, and complicated long-term data analysis. Still, the oncology field continues to push forward with promising developments emerging from key innovators like O ncolytics Biotech Inc. ONCY ONC , Cardiff Oncology, Inc. CRDF , Personalis, Inc. PSNL , Tempus AI, Inc. TEM , and Checkpoint Therapeutics, Inc. CKPT . The article continued: Additionally, the American Cancer Society has spotlighted an alarming rise in cancer incidence and mortality among younger age groups. Analysts at Exactitude Consultancy anticipate that the global Cancer Immunotherapy Market will expand at a robust 12.84% CAGR, reaching $258.22 billion by 2031 —a clear indicator of oncology's rapid growth and critical importance. Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium Oncolytics Biotech Inc. ONCY ONC , a leading clinical-stage company specializing in immunotherapy for oncology, today announced the presentation of two data sets through two abstracts showcasing pelareorep's potential in difficult-to-treat gastrointestinal cancers, which were accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco January 23-25, 2025 . "We are enthusiastic about pelareorep's applicability across multiple gastrointestinal cancer indications, including pancreatic and anal cancer," said Tom Heineman , M.D., Ph.D., Chief Medical Officer of Oncolytics . "Pelareorep engages patients' immune systems to help make commonly used chemotherapies and checkpoint inhibitors, such as atezolizumab, more effective in fighting cancer. This offers the promise of delaying disease progression and improving survival in patients with these devasting diseases. Given the versatility of pelareorep, we see multiple clinical and regulatory options for bringing this promising medicine to patients." Oncolytics will present two key data sets from the GOBLET study, with preliminary safety and tumor response results for the relapsed anal carcinoma cohort treated with pelareorep and atezolizumab presented in Poster Session C on January 25, 2025 , from 7:00 to 7:55 a.m. PT . Additionally, results from the safety run-in phase for first-line metastatic pancreatic ductal adenocarcinoma patients treated with pelareorep, modified FOLFIRINOX, with and without atezolizumab will be presented in Poster Session B on January 24, 2025 , from 11:30 a.m. to 1:00 p.m. PT . Both abstracts will be available on the ASCO Gastrointestinal Cancers Symposium website at 5:00 p.m. ET on January 21, 2025 . CONTINUED... Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ In other recent industry developments and happenings in the market include: Cardiff Oncology, Inc. CRDF , a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, recently announced positive initial data from CRDF-004, a randomized, Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). Efficacy and safety data are for all evaluable patients as of a November 26, 2024 , data cut-off date, and all efficacy data are determined by a blinded, independent central review (BICR) of each patient's tumor scan. "We are highly encouraged by the robust efficacy signal and favorable safety profile observed with onvansertib plus standard-of-care from the first 30 evaluable patients in our randomized first-line RAS-mutated mCRC CRDF-004 trial," said Fairooz Kabbinavar, MD, FACP, Chief Medical Officer of Cardiff Oncology . "Our data shows an objective response rate of 64% in patients receiving the 30 mg dose of onvansertib in combination with standard of care, significantly higher than the 33% objective response rate observed in the control arms of standard of care alone. In addition, as can be seen in the spider plots, we are observing deeper tumor response in patients receiving the 30mg dose of onvansertib compared to those receiving the 20mg dose with similar safety profiles for both doses." Personalis, Inc. PSNL , a developer of advanced cancer genomic tests and analytics, and Tempus AI, Inc. TEM , an AI-powered healthcare technology company, recently announced they've expanded their commercial relationship. Both companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus is serving as the exclusive commercial diagnostic partner for Personalis' ultra-sensitive tumor-informed MRD product, NeXT Personal® Dx, for broad patient adoption in breast and lung cancers, and for immunotherapy monitoring across all solid tumors. "While we already offer NeXT Personal through our own biopharma channel, we are pleased to leverage Tempus' integrated platform as well for these biopharma customers who desire to combine NeXT Personal with other Tempus products," said Chris Hall , CEO of Personalis . "We believe the expansion of the relationship with Tempus will accelerate market penetration of our leading ultra-sensitive MRD platform and allow us to better capitalize on the opportunity." Under this expanded relationship, Tempus will be enabled to offer Personalis' NeXT Personal MRD product to pharmaceutical and biotech customers who wish to bundle MRD testing with other Tempus offerings in a given study. Checkpoint Therapeutics, Inc. CKPT , a commercial-stage immunotherapy and targeted oncology company focused on novel treatments for patients with solid tumor cancers, recently announced that the FDA approved its UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. UNLOXCYT is the first and only programmed death ligand-1 (PD-L1) blocking antibody to receive FDA marketing approval for this indication. "[This] FDA approval of UNLOXCYT – the first marketing approval for our company – is a significant milestone both for Checkpoint and for patients with advanced cSCC," said James Oliviero , President and CEO of Checkpoin t. "This approval marks Checkpoint's transformation to a commercial-stage company, with the opportunity to compete in a U.S. market estimated to exceed $1 billion annually, where we believe UNLOXCYT offers a differentiated treatment option versus available therapies by binding to PD-L1, rather than programmed death receptor-1 (PD-1), to release the inhibitory effects of PD-L1 on the anti-tumor immune response. Additionally, UNLOXCYT has demonstrated the ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC), another potential differentiating feature of the drug compared to existing marketed therapies for patients with cSCC." Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ CONTACT: USA NEWS GROUP info@usanewsgroup.com (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. View original content: https://www.prnewswire.com/news-releases/oncology-advancements-accelerate-amid-rising-early-onset-cancer-diagnoses-302337555.html SOURCE USA News Group © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Last week, Joel Bray turned 44. “That’s pretty old for a dancer,” he reflects. Over the past 12 months Bray has toured works across Australia and Europe, taken up a new role as associate artist at Geelong Arts Centre, and begun the creative process on a yet-to-be-announced project. Choreographers and dancers Alisdair Macindoe, Tra Mi Dinh and Joel Bray Credit: Arsineh Houspian “I’ve had a big dancing year, and my body’s quite tired – it doesn’t bounce back like it once did.” Instead of trying to hold onto something that is slipping away, however, he’s leaning into the changes to his body through a new work, Swallow . “I’ve really been exploring how I can work with ease and kind of with my age, rather than against my age – rather than trying to replicate how I once used to dance when I was younger and fitter.” Swallow is a means for Bray to explore a few different threads of his life. “A lot of my work is interested in the intersection of my identity as a Wiradjuri man with my identity as a queer man.” Joel Bray. Credit: Arsineh Houspian In his previous work, Homo Pentecostus , he explored how he adopted the Welcome Swallow as his totem – a thread he has picked up here. “She’s flirty and she darts around and she’s super social,” he explains. “ Swallow is really an exploration of birds, and the movement of birds, and my affection for this animal. But also I love a double entendre,” he adds with a laugh. “So I also enjoy the other meaning of swallow – and the work is very, very queer.” Bray’s work is one of three commissioned by Lucy Guerin Inc and UMAC (University of Melbourne Arts and Culture) for Pieces , an annual series where choreographers are given three weeks to come up with a 20-minute work. Pieces has been running since 2005, and over 19 years has grown from a program that originally only had space for 20 audience members, to being performed this year in Melbourne University’s Union Theatre. Lucy Guerin started Pieces in 2005. Credit: Arsineh Houspian “It’s one of my favourite programs that we do in the year,” says renowned Australian choreographer Lucy Guerin. One of the key things she highlights is not just the strength of the individual works, but the way they interact and connect with each other. “Each year the three works sit together, and sometimes they’re really, really different,” she says. “This year, it does feel like they’re a little more connected. So it’s always a surprise as to what the whole evening will be like, and what the kind of impression that the whole evening will give to the audience.” Loading This year, Bray’s work is joined by “OK, bye!” by Alisdair Macindoe, a meditation on death and the afterlife, and Seven dances for two people by Tra Mi Dinh, an exploration of the significance behind the number seven. “OK, Bye!” began as a collaboration between Macindoe and his mother, concert harpist xanya mamunya, and is dedicated to her. “I grew up listening to her practicing in the lounge room my entire childhood,” Macindoe explains. “I think I became a dancer partly due to waking up in the morning to someone playing concert harp music.” The work marries music, dance and technology in surprising ways, perhaps most so through the self-playing instruments featured on stage. “[They] are all acoustic instruments that are played mechanically by some sort of, like, robotics or electronic mechanics that I’ve built myself in collaboration with a friend of mine who does the firmware,” explains Macindoe. Seven dances for two people , meanwhile – a duet with dancer Rachel Coulson – initially sprung from Dinh being drawn to the number seven. “It just comes up so many times again and again, across cultures, across place and time,” she says, pointing to constellations, musical notes and the number of colours in the spectrum. Loading “It’s my favourite number, and I was really keen to have a bit of a play around with what the rhythmic structures of a seven can do to movement.” All three dancers are recipients of the Chloe Munro Bequest , which offered funds to 20 dancers and choreographers to use however they see fit. The impact of the funds can be seen in both overt and more quiet ways. For both Dinh and Bray, the funds meant that when faced with the crossroads of whether to keep pursuing dance as a career, they were given both the means and the confidence to continue. “It was an incredible boost for my own self-confidence in my practice,” says Dinh. “It’s almost impossible to describe how deeply the Munro fellowship has impacted my practice, and it does directly relate to this, because to build those acoustic instruments and robotics was something I was able to do,” says Macindoe. “What it means is I can dream bigger.” Pieces is at Melbourne University’s Union Theatre from November 28 to 30. The Booklist is a weekly newsletter for book lovers from Jason Steger. Get it every Friday . Save Log in , register or subscribe to save articles for later. License this article Arts What’s on See & Do For subscribers Performing arts Elizabeth Flux is Arts Editor at The Age. Connect via Twitter or email . Most Viewed in Culture Loading

Trump names billionaire investment banker Warren Stephens as his envoy to BritainSAN JOSE, Costa Rica (AP) — The Inter-American Court of Human Rights ruled Monday that the Venezuelan government violated the political rights of former opposition presidential candidate Henrique Capriles . The court, based in Costa Rica’s capital, said in a statement that the government violated his freedom of expression, his right to equality under the law and judicial protections. Capriles, an upper-middle class lawyer, used his charisma and non-combative style to win the support of millions and become an electoral threat to the since deceased President Hugo Chávez in 2012. Capriles would lose that election, and another the following year after Chávez’s death, to current President Nicolás Maduro. It was during that second bid in 2013 that the court on Monday said the government violated Capriles’ rights and favored Maduro. State resources were used to bolster Maduro’s candidacy, the court said. Even so, the result was exceedingly close. The court ruled that Venezuela’s government undermined the integrity of the election and affected the right of Venezuelans to freely elect their leader. RELATED COVERAGE Trump’s tariff threats create division between Canada and Mexico over security at borders A small migrant caravan sets out from southern Mexico but it’s unlikely to reach the US border Catholic church calls on president of El Salvador not to lift ban on gold mining In 2017, Maduro’s administration barred Capriles from running again for 15 years . Capriles already had a ruling from the Inter-American Court of Human Rights in his favor. The court had ordered the Venezuelan government to lift the ban on his political participation, but it was ignored. In January, the Supreme Justice Tribunal ratified Capriles’ ban until 2032. In July, Maduro was declared the winner of an election full of irregularities for which tally sheets from poll places gathered by the opposition showed their candidate, Edmundo González, had defeated Maduro by a wide margin. But Venezuela’s National Electoral Council, which is stacked with Maduro loyalists, declared him the election winner hours after polls closed. ____ Follow AP’s coverage of Latin America and the Caribbean at https://apnews.com/hub/latin-america

"Last night and this morning, several of President Trump's Cabinet nominees and Administration appointees were targeted in violent, unAmerican threats to their lives and those who live with them," Trump transition spokesperson Karoline Leavitt said in a statement. She said the attacks "ranged from bomb threats to 'swatting.' In response, law enforcement and other authorities acted quickly to ensure the safety of those who were targeted. President Trump and the entire Transition team are grateful for their swift action." Swatting entails generating an emergency law enforcement response against a target victim under false pretenses. The FBI said in a statement that it is "aware of numerous bomb threats and swatting incidents targeting incoming administration nominees and appointees, and we are working with our law enforcement partners. We take all potential threats seriously, and as always, encourage members of the public to immediately report anything they consider suspicious to law enforcement." Among those targeted was New York Rep. Elise Stefanik, Trump's pick to serve as the next ambassador to the United Nations. Her office said that, Wednesday morning, she, her husband, and their 3-year-old son were driving home from Washington for Thanksgiving when they were informed of a bomb threat to their residence in Saratoga County. "New York State, County law enforcement, and U.S. Capitol Police responded immediately with the highest levels of professionalism," her office said in a statement. "We are incredibly appreciative of the extraordinary dedication of law enforcement officers who keep our communities safe 24/7." In Florida, meanwhile, the Okaloosa County sheriff's office said in an advisory posted on Facebook that it "received notification of a bomb threat referencing former Congressman Matt Gaetz's supposed mailbox at a home in the Niceville area around 9 a.m. this morning." While a family member resides at the address, they said "former Congressman Gaetz is NOT a resident. "The mailbox however was cleared and no devices were located. The immediate area was also searched with negative results." Gaetz was Trump's initial pick to serve as attorney general, but he withdrew from consideration amid allegations that he paid women for sex and slept with underage women. Gaetz has vehemently denied any wrongdoing and said last year that a Justice Department investigation into sex trafficking allegations involving underage girls had ended with no federal charges against him. The threats follow a political campaign marked by unusual violence. In July, a gunman opened fire at a Trump rally in Butler, Pennsylvania, grazing the then-candidate in the ear with a bullet and killing one of his supporters. The U.S. Secret Service later thwarted a subsequent assassination attempt at Trump's West Palm Beach, Florida, golf course when an agent spotted the barrel of a gun poking through a perimeter fence while Trump was golfing.

How Baddie Hub is Transform Social Media By Story Viewer

CALGARY, Alberta – Minnesota Wild goalie Marc-Andre Fleury bounded down the tunnel and onto the ice for his 1,000th NHL start and what was presumably the final start of his career in the home rink of the Edmonton Oilers — a team he’d beaten 16 times previously in his career. ADVERTISEMENT He corralled one of the dozens of pucks strewn around the ice and fired toward the cage he would soon be guarding. But his attempt at an empty-net goal was foiled when the puck he had shot hit another puck at the top of the crease and both slid to the corners of the rink. It was just the first thing that would go wrong for the guy teammates lovingly call “Flower” on this night. Less than 30 seconds into the game, he swung at a puck bouncing in his direction all the way from the red line. He missed, and the Oilers led 1-0 on a fluke that had the Rogers Place crowd roaring and smiling. After the initial shock wore off, Fleury was smiling too. “I haven’t played in so long, I wanted to do well and help the team, and at the beginning to let that one in, I was mad for a little bit and then I just laughed. It was so stupid,” he said following Minnesota’s 5-3 win, which gave him a 4-0-1 record for the season. “The guys came by and they gave me a tap, and they laughed and kind of made it a little lighter. And they battled well, nobody sat back.” ADVERTISEMENT Just under 60 minutes of game time later, Flower was the one grinning in the Wild locker room as Minnesota won its ninth road game in a dozen opportunities. Fleury finished with 28 saves, and the other two Edmonton goals both went off the skates of Wild defenders. In the first period, he made a sprawling poke-check save to thwart Oilers star Connor McDavid’s rush to the net that had the Edmonton crowd primed to explode again. It was the 1,030th appearance in an NHL game for Fleury, moving him past Patrick Roy into third in the NHL record books for most games played by a goalie. He will turn 40 on Thanksgiving Day and has been in the league since 2003, after the Penguins made him the first-overall pick in that summer’s draft. But with Filip Gustavsson off to a fantastic start as the Wild’s mainstay in the crease, and Jesper Wallstedt waiting in the wings (in Iowa) presumably as the franchise’s goalie of the future, Fleury finds himself in a new role: backup goalie. Perhaps the only time his ever-present smile seemed forced following the win in Edmonton was when Fleury pointed out, on two occasions, that it was his first start in three weeks, since a win at San Jose on Nov. 7. ADVERTISEMENT Minnesota coach John Hynes reiterated on Friday afternoon that there was, for a brief moment, a thought that the Wild would carry three goalies — Gustavsson, Fleury and Wallstedt — for a time in October, meaning there would be two backups, or a rotation plus a third stringer. It didn’t work out that way. “Gus and Flower played well. Wally played well. But based on contracts and things like that and where everyone’s at in their career, Wally went down and played (in Iowa) and he’s doing a good job now and has found his game,” Hynes said. “But Flower’s playing really well and Gus is playing really well. So, it hasn’t been that he’s...the understudy. It’s just, here’s what we need to do everyday and then we’ll try to let you know when we’re going to start. Sometimes, it might be in advance. Sometimes, it might be a little closer to the game.” Fleury has made it clear that this will be the final season of his career, so like a rare flower that only blooms once in a while, seeing one of his remaining starts is worth seeking out. Of course, with the Wild defying expectations, the team’s fanbase is clearly hoping this flower keeps blooming well into May or even June. ADVERTISEMENT ______________________________________________________ This story was written by one of our partner news agencies. Forum Communications Company uses content from agencies such as Reuters, Kaiser Health News, Tribune News Service and others to provide a wider range of news to our readers. Learn more about the news services FCC uses here .

Panaji: Former industries minister Suresh Parulekar passed away at the age of 82 after a brief illness in Panaji on Monday. His daughter Nirupa Pawar confirmed the news of his death. Parulekar is survived by a wife, two daughters and a son. Parulekar started his political career as a panch of Reis Magos panchayat in 1967, and later went to become the sarpanch. He was first elected to the Goa legislative assembly on Congress ticket from Calangute in 1989. He was made minister in 1991 under Ravi Naik headed the govt. During his tenure as minister for industries, he announced the first industrial policy of the state. Stay updated with the latest news on Times of India . Don't miss daily games like Crossword , Sudoku , and Mini Crossword . Spread love this holiday season with these Christmas wishes , messages , and quotes.

Artificial Intelligence Infiltrating Healthcare in Illinois and its Effects on Insurers

Trudeau dijo a Trump que aranceles también perjudicarán a estadounidenses, según ministro canadienseStocks rose in afternoon trading on Wall Street Friday, keeping the market on track for its fifth gain in a row. The S&P 500 was up 0.3% and was solidly on track for a weekly gain that will erase most of last week's loss. The Dow Jones Industrial Average climbed 352 points, or 0.8%, and the Nasdaq composite rose 0.1% as of 2:05 p.m. Eastern. Markets have been volatile over the last few weeks, losing ground in the runup to elections in November, then surging following Donald Trump's victory, before falling again. The S&P 500 has been steadily rising throughout this week to within close range of its record. “Overall, market behavior has normalized following an intense few weeks,” said Mark Hackett, chief of investment research at Nationwide, in a statement. Several retailers jumped after giving Wall Street encouraging financial updates. Gap soared 10.8% after handily beating analysts' third-quarter earnings and revenue expectations, while raising its own revenue forecast for the year. Discount retailer Ross Stores rose 2.2% after raising its earnings forecast for the year. EchoStar fell 3.3% after DirecTV called off its purchase of that company's Dish Network unit. Smaller company stocks had some of the biggest gains. The Russell 2000 index rose 1.7%. A majority of stocks in the S&P 500 were gaining ground, but those gains were kept in check by slumps for several big technology companies. Nvidia fell 3.2%. Its pricey valuation makes it among the heaviest influences on whether the broader market gains or loses ground. The company has grown into a nearly $3.6 trillion behemoth because of demand for its chips used in artificial-intelligence technology. Intuit, which makes TurboTax and other accounting software, fell 5.6%. It gave investors a quarterly earnings forecast that fell short of analysts’ expectations. Facebook owner Meta Platforms fell 0.8% following a decision by the Supreme Court to allow a multibillion-dollar class action investors’ lawsuit to proceed against the company. It stems from the privacy scandal involving the Cambridge Analytica political consulting firm. European markets were mostly higher and Asian markets ended mixed. Crude oil prices rose. Treasury yields held relatively steady in the bond market. The yield on the 10-year Treasury fell to 4.40% from 4.42% late Thursday. In the crypto market, Bitcoin hovered around $99,000, according to CoinDesk. It has more than doubled this year and first surpassed the $99,000 level on Thursday. Retailers remained a big focus for investors this week amid close scrutiny on consumer spending habits headed into the holiday shopping season. Walmart, the nation's largest retailer, reported a quarter of strong sales and gave investors an encouraging financial forecast. Target, though, reported weaker earnings than analysts' expected and its forecast disappointed Wall Street. Consumer spending has fueled economic growth, despite a persistent squeeze from inflation and high borrowing costs. Inflation has been easing and the Federal Reserve has started trimming its benchmark interest rates. That is likely to help relieve pressure on consumers, but any major shift in spending could prompt the Fed to reassess its path ahead on interest rates. Also, any big reversals on the rate of inflation could curtail spending. Consumer sentiment remains strong, according to the University of Michigan's consumer sentiment index. It revised its latest figure for November to 71.8 from an initial reading of 73 earlier this month, though economists expected a slight increase. It's still up from 70.5 in October. The survey also showed that consumers' inflation expectations for the year ahead fell slightly to 2.6%, which is the lowest reading since December of 2020. Wall Street will get another update on how consumers feel when the business group The Conference Board releases its monthly consumer confidence survey on Tuesday. A key inflation update will come on Wednesday when the U.S. releases its October personal consumption expenditures index. The PCE is the Fed's preferred measure of inflation and this will be the last PCE reading prior to the central bank's meeting in December.